Minerva Neurosciences (NERV) Competitors $1.74 +0.01 (+0.58%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NERV vs. MURA, QNCX, KPTI, FBRX, IMMX, ZIVO, NBRV, PRLD, SKYE, and CTORShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Mural Oncology (MURA), Quince Therapeutics (QNCX), Karyopharm Therapeutics (KPTI), Forte Biosciences (FBRX), Immix Biopharma (IMMX), ZIVO Bioscience (ZIVO), Nabriva Therapeutics (NBRV), Prelude Therapeutics (PRLD), Skye Bioscience (SKYE), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. Mural Oncology Quince Therapeutics Karyopharm Therapeutics Forte Biosciences Immix Biopharma ZIVO Bioscience Nabriva Therapeutics Prelude Therapeutics Skye Bioscience Citius Oncology Mural Oncology (NASDAQ:MURA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability. Does the media favor MURA or NERV? In the previous week, Mural Oncology had 3 more articles in the media than Minerva Neurosciences. MarketBeat recorded 5 mentions for Mural Oncology and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.94 beat Mural Oncology's score of 0.40 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mural Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in MURA or NERV? Minerva Neurosciences received 339 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 80.00% of users gave Mural Oncology an outperform vote while only 55.79% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMural OncologyOutperform Votes880.00% Underperform Votes220.00% Minerva NeurosciencesOutperform Votes34755.79% Underperform Votes27544.21% Which has higher valuation and earnings, MURA or NERV? Mural Oncology is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMural OncologyN/AN/A-$207.45M-$7.58-0.34Minerva NeurosciencesN/AN/A-$30M$0.199.13 Which has more volatility & risk, MURA or NERV? Mural Oncology has a beta of 5.28, suggesting that its stock price is 428% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Do insiders and institutionals have more ownership in MURA or NERV? 80.2% of Mural Oncology shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 0.1% of Mural Oncology shares are owned by insiders. Comparatively, 8.6% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is MURA or NERV more profitable? Minerva Neurosciences' return on equity of 0.00% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Mural OncologyN/A -70.10% -61.30% Minerva Neurosciences N/A N/A -6.74% Do analysts rate MURA or NERV? Mural Oncology currently has a consensus price target of $13.00, indicating a potential upside of 399.04%. Minerva Neurosciences has a consensus price target of $5.00, indicating a potential upside of 188.18%. Given Mural Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Mural Oncology is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryMural Oncology beats Minerva Neurosciences on 8 of the 15 factors compared between the two stocks. Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.13M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-3.947.3822.6318.55Price / SalesN/A241.88397.30103.38Price / CashN/A65.8538.1834.62Price / Book-0.436.476.704.25Net Income-$30M$143.68M$3.23B$248.27M7 Day Performance-0.86%1.85%1.36%1.28%1 Month Performance11.94%6.73%3.85%3.75%1 Year Performance-27.71%-2.72%15.87%5.31% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences3.7992 of 5 stars$1.74+0.6%$5.00+188.2%-29.2%$12.13MN/A-3.949Negative NewsMURAMural Oncology3.2258 of 5 stars$2.69-0.4%$13.00+383.3%-28.9%$46.34MN/A-0.29119QNCXQuince Therapeutics2.838 of 5 stars$1.05+6.0%$8.00+661.9%+2.8%$46.29MN/A-0.8560News CoverageKPTIKaryopharm Therapeutics3.6369 of 5 stars$5.40+9.1%$57.50+964.8%-56.3%$46.28M$145.24M-5.29380Upcoming EarningsShort Interest ↑News CoverageFBRXForte Biosciences3.4931 of 5 stars$7.01-4.5%$32.50+363.6%+24,865.8%$46.14MN/A-0.435Options VolumePositive NewsGap DownIMMXImmix Biopharma3.3078 of 5 stars$1.66+1.2%$7.00+321.7%-2.8%$46.02MN/A-1.959Upcoming EarningsShort Interest ↓News CoveragePositive NewsZIVOZIVO BioscienceN/A$12.00-25.0%N/A+138.0%$45.49M$15,850.00-2.4610News CoverageGap DownHigh Trading VolumeNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070Analyst ForecastPRLDPrelude Therapeutics2.8973 of 5 stars$0.80-1.4%$4.00+400.8%-74.5%$45.09M$7M-0.45120Upcoming EarningsAnalyst ForecastNews CoverageSKYESkye Bioscience1.3404 of 5 stars$1.53-44.1%$16.60+988.5%-83.1%$44.45MN/A-2.1211CTORCitius OncologyN/A$0.62-7.6%$3.00+383.1%N/A$44.43MN/A0.00N/ANews CoveragePositive NewsGap Down Related Companies and Tools Related Companies Mural Oncology Alternatives Quince Therapeutics Alternatives Karyopharm Therapeutics Alternatives Forte Biosciences Alternatives Immix Biopharma Alternatives ZIVO Bioscience Alternatives Nabriva Therapeutics Alternatives Prelude Therapeutics Alternatives Skye Bioscience Alternatives Citius Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NERV) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
